News
Focusing on innovative 3D cell technology products and services
News
/
/
/
Caring for Women's Health | Clinical Studies on Stem Cell Therapy for Treating Women's Diseases

Caring for Women's Health | Clinical Studies on Stem Cell Therapy for Treating Women's Diseases

  • Categories:Company News
  • Author:CytoNiche
  • Origin:CytoNiche
  • Time of issue:2024-03-12
  • Views:139

(Summary description)Exploring new treatment options for various women's diseases using the unique characteristics of stem cells can provide more effective medical choices for countless women.

Caring for Women's Health | Clinical Studies on Stem Cell Therapy for Treating Women's Diseases

(Summary description)Exploring new treatment options for various women's diseases using the unique characteristics of stem cells can provide more effective medical choices for countless women.

  • Categories:Company News
  • Author:CytoNiche
  • Origin:CytoNiche
  • Time of issue:2024-03-12
  • Views:139
Information

Introduction

Stem cell therapy, as a means of regenerative medicine, is hailed as the third medical revolution following drug therapy and surgical treatment, offering new possibilities for the treatment of various refractory diseases. In clinical research on treating women's diseases, scientists are also committed to exploring new treatment options using the unique characteristics of stem cells, providing more effective medical choices for women.

 

Some Indications

1:Endometriosis

Endometriosis (EMS) is one of the most common benign diseases in gynecology. In recent years, more and more studies have shown that apoptosis plays an important role in clearing ectopic endometrial cells and maintaining the stability of the intracellular environment during the menstrual cycle.

Umbilical cord mesenchymal stem cells can secrete various cytokines through paracrine effects, including anti-apoptotic molecules, immune regulatory molecules, angiogenesis molecules, chemotactic molecules, etc., thereby regulating the biological activity of cells and participating in tissue repair processes. Studies have found that changes in PTEN gene expression are associated with various endometrial-related lesions and are considered to be the "caretaker gene" in endometrial tissue.

Table 1: Clinical Application of hUC-MSCs in Endometrial Injury Diseases [1]

Research on stem cell-based treatment strategies for endometriosis (EMS) has also achieved certain results. This includes genetic modification of stem cells or inhibition of stem cell characteristics, reducing the migration and transplantation of endometrial-derived stem cells and bone marrow-derived stem cells to endometriotic lesions, thus providing new insights into EMS treatment.

2:Intrauterine adhesions
Intrauterine adhesions (IUA), also known as Asherman's syndrome, are a common gynecological disorder. The main manifestation of IUA is partial or complete occlusion of the uterine cavity, leading to a series of symptoms such as insufficient menstrual bleeding or amenorrhea, dysmenorrhea, chronic pelvic pain, and even infertility or recurrent miscarriage, which seriously affect women's reproductive health. Although many methods have been used to treat severe intrauterine adhesions, their treatment efficacy is limited due to the high recurrence rate and thinning of the endometrium.

Research has shown that umbilical cord mesenchymal stem cells can effectively prevent postoperative intrauterine adhesions, promote endometrial healing, increase endometrial thickness, glandular numbers, and inhibit endometrial fibrosis tendency.

Compared with the use of collagen scaffolds or umbilical cord mesenchymal stem cells alone, the combination of collagen scaffolds and umbilical cord mesenchymal stem cells significantly increases the number of endometrial glands and reduces fibrotic areas, potentially representing a new approach for treating intrauterine adhesions.

3:Premature ovarian insufficiency
Premature ovarian insufficiency (POI) refers to ovarian dysfunction occurring before the age of 40 due to various causes. In recent years, POI has shown an increasing trend and a tendency to occur at a younger age. Currently, the main clinical treatment for POI is hormone replacement therapy, which can alleviate symptoms related to low estrogen levels but cannot reverse ovarian function. Moreover, it has been shown to increase the risk of breast cancer, venous thrombosis, endometrial cancer, and ovarian cancer.

Research suggests that due to the low immunogenicity, wide availability, and broad source of mesenchymal stem cells (MSCs), their transplantation is an excellent choice for basic POI treatment. The therapeutic effect of MSCs is not regulated by a single factor but involves complex biological regulation. After MSCs migrate to the damaged ovaries, they regulate cell proliferation, apoptosis, immunity, autophagy, oxidative stress, and fibrosis of ovarian cells through paracrine effects.

Figure 1: Mechanism of Mesenchymal Stem Cell Therapy for Premature Ovarian Insufficiency [5]

Tissue engineering and extracellular vesicles are new technologies for mesenchymal stem cell (MSC) therapy, aimed at improving the treatment outcomes for patients with premature ovarian insufficiency (POI). Establishing standardized systems for MSCs, from cultivation to application, can enhance the safety of MSC-based therapies and mitigate potential side effects. In summary, MSC-mediated therapy holds vast potential for fundamental restoration of ovarian function in POI patients.

 

Challenges

It is believed that with further research in the scientific community on stem cell technology, stem cells will play a greater role in disease treatment and women's health. However, in this process, ensuring the quality and uniformity of stem cell production remains a key foundation for the clinical application and commercialization of stem cell therapy products.

At present, traditional two-dimensional cell culture methods are still widely used for stem cell production, which can only increase cell yield by increasing the number of culture bottles (horizontal) or using more layers of cell factories (vertical). This approach not only incurs significant costs in terms of manpower, time, and space, but also leads to high costs and large batch-to-batch differences in cell quality, making it difficult to meet the GMP capacity expansion requirements for cell therapy products.

Furthermore, two-dimensional culture methods cannot maintain the original characteristics of stem cells over the long term and cannot accurately describe or simulate the rich microenvironments and complex behavioral changes of cells in the human body, such as signal transduction and spatial structural changes. Therefore, data collected using two-dimensional cell culture methods may be misleading for predicting their in vivo applications.

 

Breakthroughs

The use of three-dimensional cell culture methods can better simulate the three-dimensional microenvironment of cells in the body, including cell-cell interactions, cell-matrix interactions, and the distribution of cells in three-dimensional space. This approach can better reproduce or retain the structure and function of cells in tissues in vivo, providing more realistic and reliable data for research or drug screening, and facilitating a more accurate understanding of physiological and pathological processes. Three-dimensional cell culture can also provide deeper insights into the behavior and characteristics of stem cells, leading to revolutionary breakthroughs in medical research and treatment.

As a high-quality expert in three-dimensional cell manufacturing, Huagan Bio has developed a pioneering "hundred-billion-level" stem cell production solution based on its core original products, the 3D TableTrix® microcarrier and 3D FloTrix® cell culture technology, together with a series of cell culture, harvesting, and packaging equipment. The entire production process adopts a fully enclosed, automated process, capable of real-time detection of cell quantity and quality. Cells can be expanded and cultured to reach a hundred billion quantity in just 13 days, and the final cell preparation adheres to strict quality inspection and library establishment standards.

Figure 2: Huagan Bio's "Hundred-Billion-Level" Cell Production Process

Additionally, Huagan Bio can design customized three-dimensional expansion and culture processes for mesenchymal stem cells based on the growth characteristics of MSCs from different tissue sources, meeting various cell culture needs and achieving breakthroughs in both "quality" and "quantity" of cell production.

 

Reference

[1] 刘星妤, 胡小芳, 徐广立, 王 瑞, 李佩瑶, 王梦园, 彭 丽, 朱香颖. 人脐带间充质干细胞修复子宫内膜损伤[J]. 中国组织工程研究, 2022, 26(24): 3921-3927.

[2] 艾瑛 , 廖诗平 , 王玉芳 , 等 . 脐带间充质干细胞移植预防宫腔粘连的研究 [J]. 现代妇产科进展 ,2019,28(5):342-345.

[3] 江春燕 . 左归丸联合脐带间充质干细胞修复受损子宫内膜的研究 [D]. 武汉 : 湖北中医药大学 ,2017

[4] LIU Y, CAI J, LUO X, et al. Collagen scaffold with human umbilical cord mesenchymal stem cells remarkably improves intrauterine adhesions in a rat model. Gynecol Obstet Invest. 2020;85(3):267-276.

[5] Li Z, Zhang M, Tian Y, Li Q, Huang X. Mesenchymal Stem Cells in Premature Ovarian Insufficiency: Mechanisms and Prospects. Front Cell Dev Biol. 2021 Aug 3;9:718192. doi: 10.3389/fcell.2021.718192. PMID: 34414193; PMCID: PMC8369507.



[About CytoNiche]

CytoNiche was established in 2018, led by Professor Yanan Du's research team from the School of Medicine at Tsinghua University, with Tsinghua University as a shareholder. The core technology originated from the transformation of scientific achievements at Tsinghua University and was recognized as a leading technology in "Science and Technology Innovation in China" by the China Association for Science and Technology. As a national-level high-tech enterprise, a national-level specialized and new technology "Little Giant" enterprise, a potential unicorn enterprise, it has also received key research and development special support from the Ministry of Science and Technology.

As an expert in high-quality three-dimensional cell manufacturing, CytoNiche provides a one-stop customized solution for cell scale-up based on 3D microcarriers. The company has built an original 3D cell smart manufacturing platform, achieving large-scale, automated, intelligent, and closed-cell drug and derivative production preparation. This helps global customers establish the most advanced cell drug production lines. After pioneering the production process pipeline for "billion-level" stem cells, the company is accelerating towards "hundred billion-level," dedicating efforts to empower the cell and gene therapy industry with 3D cell scale-up smart manufacturing technology to benefit more patients.

Keyword:

Scan the QR code to read on your phone

Latest News

Copyright: Beijing CytoNiche Biotechnology Co., Ltd.
Copyright: Beijing CytoNiche Biotechnology Co., Ltd.